DelveInsight’s “Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Iron Deficiency Anemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Iron Deficiency Anemia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Key highlights from the Iron Deficiency Anemia Market Report:
-
In 2023, the Iron Deficiency Anemia market size across the 7MM (United States, EU4, UK, and Japan) was approximately USD 1,400 million. The market is expected to see significant growth due to increased adoption of existing treatments, the anticipated launch of one-time gene therapies, and greater awareness of the condition.
-
The United States holds the largest share of the Iron Deficiency Anemia market, accounting for about 78%, compared to the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
-
Oral Ferrous Products (OFPs), including ferrous sulfate, ferrous fumarate, and ferrous gluconate, are the most common treatments for IDA due to their cost-effectiveness. However, OFPs currently represent only 10-15% of the total IDA market. This is largely due to the prevalence of generic versions and issues with patient adherence, primarily due to gastrointestinal side effects.
-
In the early stages of IDA, particularly mild to moderate cases, oral iron supplements are often prescribed. These supplements come in various forms, including tablets, pills, and syrups. In 2019, the FDA approved ACCRUFER for adults who had previously discontinued oral ferrous products due to ineffectiveness or intolerance. Similarly, in 2017, the FDA approved AURYXIA for treating IDA in adults with chronic kidney disease (CKD) who were intolerant of or had an inadequate response to oral iron supplements.
-
Due to low adherence rates to oral iron supplements, intravenous iron options are considered more effective. Options include INJECTAFER, VENOFER, and FERAHEME. However, these treatments often require clinic visits for administration and can impact patients’ quality of life.
-
Rockwell Medical introduced TRIFERIC (dialysate) and TRIFERIC AVNU (intravenous) in the U.S. in late 2019 and early 2021, respectively. Despite these launches, limited market adoption, unfavorable reimbursement, and a lack of interest from other companies led Rockwell Medical to discontinue the NDA for TRIFERIC and TRIFERIC AVNU in the fourth quarter of 2022.
-
The IDA market is expected to grow due to the introduction of new oral iron supplements with fewer side effects, an increase in IDA cases driven by lifestyle changes and risk factors like malaria, and other factors. However, widespread use of OTC medications, the availability of generics, the economic burden on patients, and a lack of a robust pipeline could hinder market growth.
Read detailed insights on Iron Deficiency Anemia market outlook 2034 @ https://www.delveinsight.com/sample-request/iron-deficiency-anemia-market
Iron Deficiency Anemia Overview
Iron deficiency anemia (IDA) is the most common type of anemia, occurring when the body does not have enough iron to produce sufficient hemoglobin. Hemoglobin is essential for transporting oxygen throughout the body, so low iron levels can impair oxygen delivery. The severity of IDA can range from mild to severe, depending on the degree of iron deficiency.
Diagnosing IDA generally starts with a complete blood count (CBC) test, followed by additional blood tests to evaluate the extent of the deficiency and identify potential causes. These further tests often include measuring iron levels, ferritin, and total iron-binding capacity, as well as assessing reticulocyte counts and examining peripheral blood smears. If gastrointestinal bleeding is suspected, diagnostic procedures such as fecal occult blood tests, upper endoscopy, and colonoscopy may be performed. Additional tests might be conducted to assess inflammation markers, nutrient levels, and bone marrow health to pinpoint the underlying cause of the anemia.
The Iron Deficiency Anemia report offers a thorough overview of its pathophysiology, diagnostic approaches, and treatment strategies, including real-world examples of patient experiences from symptom onset through diagnosis and management.
Treatment for Iron Deficiency Anemia
The treatment for IDA varies based on its cause and severity and may involve iron supplements, medical procedures, surgery, and dietary adjustments. For severe cases, intravenous (IV) iron therapy or a blood transfusion may be necessary. The primary goals of treatment are to address the underlying cause of IDA and to restore normal levels of red blood cells, hemoglobin, and iron.
If gastrointestinal bleeding is the cause, procedures such as upper endoscopy or colonoscopy may be performed to stop the bleeding. For patients with chronic kidney disease and IDA, erythropoiesis-stimulating agents (ESAs) may be prescribed. These medications stimulate the bone marrow to produce more red blood cells and are typically used in conjunction with iron therapy or IV iron, particularly if iron therapy alone is insufficient.
For patients who cannot tolerate or absorb oral iron supplements—such as those who have had gastrectomy, gastrojejunostomy, bariatric surgery, or other small bowel surgeries—parenteral (injectable) iron therapies may be used. Common parenteral iron options include VENOFER, FERINJECT, FERAHEME, and MONOFER.
Iron Deficiency Anemia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
Iron Deficiency Anemia Epidemiology Insights:
-
In 2023, the total number of prevalent cases of Iron Deficiency Anemia (IDA) in the United States was approximately 9,510,600. Among the EU4 countries (Germany, Spain, Italy, France) and the UK, the UK had the highest number of diagnosed prevalent cases, while France reported the fewest.
-
According to estimates from DelveInsight’s consultants, about two-thirds of the diagnosed cases of IDA were classified as mild. The condition was notably more common in women than in men, with women accounting for approximately 65% of cases in 2023.
-
In the United States, IDA associated with chronic kidney disease represented around 30% of all IDA cases by pathology in 2023.
Key Iron Deficiency Anemia Companies
-
Akebia Therapeutics, Shield Therapeutics, AMAG Pharmaceuticals, Pharmacosmos Therapeutics, Vifor Pharma, Vifor Pharma, American Regent, MegaPro Biomedical, Nemysis
Iron Deficiency Anemia Therapies
-
MPB-1514 (IOP Injection), IDAX (IHAT-02), FERACCRU/ACCRUFeR (Ferric Maltol/ ST10), MONOFER (Iron Isomaltoside 1000/ Monoferric/ ferricderisomaltose/ NS-32)
Learn How the Iron Deficiency Anemia Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/iron-deficiency-anemia-market
Iron Deficiency Anemia Market Outlook
Effectively managing Iron Deficiency Anemia (IDA) involves diagnosing the underlying cause of the iron deficiency and implementing appropriate treatments, including dietary changes and iron supplementation. Oral iron therapy is the primary treatment for patients who do not have contraindications. Currently, IDA treatment options include oral iron supplements (both over-the-counter and prescription), parenteral iron therapies (such as intravenous treatments), blood transfusions, surgical interventions, and other modalities. For patients with chronic kidney disease (CKD) and IDA, erythropoiesis-stimulating agents (ESAs) may be recommended.
VENOFER (Ferric Oxyhydroxide), approved by the FDA in November 2000, is used to treat IDA in chronic hemodialysis patients receiving erythropoietin therapy. It received additional FDA approval in June 2005 for managing IDA in CKD patients not on dialysis. INJECTAFER was approved in Europe in June 2007 and in May 2021, the FDA approved a single 1000 mg dose of Injectafer for adult IDA patients who are intolerant to oral iron, have an unsatisfactory response to oral iron, or have non-dialysis dependent CKD. Other FDA-approved therapies include AURYXIA, FERACCRU/ACCRUFeR, and MONOFER. Numerous over-the-counter iron supplements and salts, available at affordable prices, are widely used by patients. These supplements are available in both ferrous and ferric salt forms, and several consumer health companies are also developing non-drug supplements to combat iron deficiency.
Despite the range of approved treatments, there are still unmet needs in the management of IDA. Companies like MegaPro Biomedical (developing MPB-1514 (IOP Injection)) and Nemysis (developing IDAX (IHAT-02)) are working on novel therapies to address these gaps and improve treatment options for IDA.
Leading Players in the Iron Deficiency Anemia Therapeutics Market Include:
Iron Deficiency Anemia Companies working in the market are Akebia Therapeutics, Shield Therapeutics, AMAG Pharmaceuticals, Pharmacosmos Therapeutics, Vifor Pharma, Vifor Pharma, American Regent, MegaPro Biomedical, Nemysis, and others.
Iron Deficiency Anemia Report Covers the In-depth Assessment of the Emerging Iron Deficiency Anemia Drugs & Key Companies. Download the Iron Deficiency Anemia Market Sample Report to Learn More @ https://www.delveinsight.com/report-store/iron-deficiency-anemia-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Iron Deficiency Anemia Competitive Intelligence Analysis
4. Iron Deficiency Anemia Market Overview at a Glance
5. Iron Deficiency Anemia Disease Background and Overview
6. Iron Deficiency Anemia Patient Journey
7. Iron Deficiency Anemia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Iron Deficiency Anemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Iron Deficiency Anemia Unmet Needs
10. Key Endpoints of Iron Deficiency Anemia Treatment
11. Iron Deficiency Anemia Marketed Products
12. Iron Deficiency Anemia Emerging Drugs and Latest Therapeutic Advances
13. Iron Deficiency Anemia Seven Major Market Analysis
14. Attribute Analysis
15. Iron Deficiency Anemia Market Outlook (In US, EU5, and Japan)
16. Iron Deficiency Anemia Access and Reimbursement Overview
17. KOL Views on the Iron Deficiency Anemia Market
18. Iron Deficiency Anemia Market Drivers
19. Iron Deficiency Anemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Trending Reports by DelveInsight:
Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, Clinical trials, Iron Deficiency Anemia prevalence, Treatment Algorithms | Akebia Therapeutics, Shield Therapeutics